Spyre Therapeutics
SYRE
SYRE
71 hedge funds and large institutions have $154M invested in Spyre Therapeutics in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 24 increasing their positions, 22 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
8% less funds holding
Funds holding: 77 → 71 (-6)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
Holders
71
Holding in Top 10
2
Calls
$19K
Puts
$1K
Top Buyers
| 1 | +$5.38M | |
| 2 | +$1.17M | |
| 3 | +$1.09M | |
| 4 |
AG
Artal Group
Luxembourg
|
+$1.01M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$520K |
Top Sellers
| 1 | -$1.49M | |
| 2 | -$1.31M | |
| 3 | -$1.28M | |
| 4 |
Millennium Management
New York
|
-$520K |
| 5 |
Man Group
London,
United Kingdom
|
-$389K |